Emerging research suggests Htt1a may play an important role in Huntington's disease. VO659 is designed to target the expanded CAG repeat within exon 1 of the mutant HTT gene, w the potential to reduce multiple toxic products while preserving normal huntingtin expression
vicotx.com/pipeline/vo6...
vicotx.com/pipeline/vo6...
VO659 – Vico Therapeutics
Targeting Genetic Drivers of Neurodegeneration Pipeline VO659 VO659 is an innovative antisense oligonucleotide (ASO) therapy that targets the genetic drivers of
vicotx.com
August 12, 2026 at 2:52 PM
Emerging research suggests Htt1a may play an important role in Huntington's disease. VO659 is designed to target the expanded CAG repeat within exon 1 of the mutant HTT gene, w the potential to reduce multiple toxic products while preserving normal huntingtin expression
vicotx.com/pipeline/vo6...
vicotx.com/pipeline/vo6...
Vico CEO Micah Mackison is presenting at BioCapital Europe 2026, sharing updates on VO659 and our global strategy for allele-preferential RNA therapies in polyglutamine diseases. Let’s connect!
#BioCapitalEurope #VO659
#BioCapitalEurope #VO659
March 4, 2026 at 9:25 AM
Vico CEO Micah Mackison is presenting at BioCapital Europe 2026, sharing updates on VO659 and our global strategy for allele-preferential RNA therapies in polyglutamine diseases. Let’s connect!
#BioCapitalEurope #VO659
#BioCapitalEurope #VO659
Vico Therapeutics’ Huntington’s disease drug VO659 is now being tested with dosing just twice a year, and the FDA has cleared the path for US clinical trials to begin later this year.
Full article: en.hdbuzz.net/vicos-trial-...
Full article: en.hdbuzz.net/vicos-trial-...
Vico’s Trial Adjusts With Twice-Yearly Dosing, And The U.S. Is Next – HDBuzz
en.hdbuzz.net
March 2, 2026 at 4:40 PM
Vico Therapeutics’ Huntington’s disease drug VO659 is now being tested with dosing just twice a year, and the FDA has cleared the path for US clinical trials to begin later this year.
Full article: en.hdbuzz.net/vicos-trial-...
Full article: en.hdbuzz.net/vicos-trial-...
We're heading to the Annual HDSA Convention in Phoenix.
Vico is proud to sponsor this year's meeting, where CMO Scott Schobel, MD, will present during the Clinical Trials Showcase and share an update on VO659. Drop us a note if you'd like to connect
#HDSAConvention #HuntingtonsDisease #RareDisease
Vico is proud to sponsor this year's meeting, where CMO Scott Schobel, MD, will present during the Clinical Trials Showcase and share an update on VO659. Drop us a note if you'd like to connect
#HDSAConvention #HuntingtonsDisease #RareDisease
June 18, 2026 at 8:16 PM
We're heading to the Annual HDSA Convention in Phoenix.
Vico is proud to sponsor this year's meeting, where CMO Scott Schobel, MD, will present during the Clinical Trials Showcase and share an update on VO659. Drop us a note if you'd like to connect
#HDSAConvention #HuntingtonsDisease #RareDisease
Vico is proud to sponsor this year's meeting, where CMO Scott Schobel, MD, will present during the Clinical Trials Showcase and share an update on VO659. Drop us a note if you'd like to connect
#HDSAConvention #HuntingtonsDisease #RareDisease
Proud to have Lodewijk Toonen represent Vico at #GRC2025 on CAG Triplet Repeat Disorders. Our lead candidate VO659 targets the root cause of Huntington's & SCAs—directly addressing CAG expansions while preserving protein function. #RareDisease
May 28, 2025 at 4:18 PM
Proud to have Lodewijk Toonen represent Vico at #GRC2025 on CAG Triplet Repeat Disorders. Our lead candidate VO659 targets the root cause of Huntington's & SCAs—directly addressing CAG expansions while preserving protein function. #RareDisease
Energized from #2025AAC! Inspired by the community and collaborative spirit as we advance our ASO platform targeting neurodegenerative disorders at their genetic foundation. Our VO659 candidate continues to show promise for multiple polyglutamine disorders.
April 9, 2025 at 11:57 AM
Energized from #2025AAC! Inspired by the community and collaborative spirit as we advance our ASO platform targeting neurodegenerative disorders at their genetic foundation. Our VO659 candidate continues to show promise for multiple polyglutamine disorders.
Grateful to have sponsored and joined the HDSA Annual Convention in Indianapolis—three inspiring days of learning, connection & community. Our CEO Micah Mackison shared insights on VO659 and our allele-selective ASO approach. Honored to walk with the HD community at Team Hope.
July 1, 2025 at 4:58 PM
Grateful to have sponsored and joined the HDSA Annual Convention in Indianapolis—three inspiring days of learning, connection & community. Our CEO Micah Mackison shared insights on VO659 and our allele-selective ASO approach. Honored to walk with the HD community at Team Hope.
Heading to #BIO2026 in San Diego? CEO Micah Mackison & VP BD & Strategy Prarthana Khanna look forward to connecting with the biotech and pharma community. Exciting momentum as VO659 moves to twice-yearly dosing & advances toward U.S. development. Let’s meet!
June 15, 2026 at 11:15 AM
Heading to #BIO2026 in San Diego? CEO Micah Mackison & VP BD & Strategy Prarthana Khanna look forward to connecting with the biotech and pharma community. Exciting momentum as VO659 moves to twice-yearly dosing & advances toward U.S. development. Let’s meet!
Research suggests Htt1a may play an important role in Huntington's disease. VO659 is designed to target the expanded CAG repeat within exon 1 of the mutant HTT gene, w potential to reduce multiple toxic products while preserving normal huntingtin expression. Learn more: vicotx.com/pipeline/vo6...
August 17, 2026 at 11:24 AM
Research suggests Htt1a may play an important role in Huntington's disease. VO659 is designed to target the expanded CAG repeat within exon 1 of the mutant HTT gene, w potential to reduce multiple toxic products while preserving normal huntingtin expression. Learn more: vicotx.com/pipeline/vo6...
Heading to the 21st Annual HD Therapeutics Conference hosted by CHDI.
We’ll share mechanistic & clinical progress on VO659, our allele-preferential ASO targeting CAG repeat expansion.
Nicole Datson, PhD (CSO): MoA insights
Scott Schobel, MD (CMO): Phase 1/2a clinical update
Let’s connect.
We’ll share mechanistic & clinical progress on VO659, our allele-preferential ASO targeting CAG repeat expansion.
Nicole Datson, PhD (CSO): MoA insights
Scott Schobel, MD (CMO): Phase 1/2a clinical update
Let’s connect.
February 20, 2026 at 3:35 PM
Heading to the 21st Annual HD Therapeutics Conference hosted by CHDI.
We’ll share mechanistic & clinical progress on VO659, our allele-preferential ASO targeting CAG repeat expansion.
Nicole Datson, PhD (CSO): MoA insights
Scott Schobel, MD (CMO): Phase 1/2a clinical update
Let’s connect.
We’ll share mechanistic & clinical progress on VO659, our allele-preferential ASO targeting CAG repeat expansion.
Nicole Datson, PhD (CSO): MoA insights
Scott Schobel, MD (CMO): Phase 1/2a clinical update
Let’s connect.
What are ASOs? Antisense Oligonucleotides are synthetic molecules that bind to RNA targets, blocking harmful proteins and enabling precise gene modulation. At Vico, our VO659 ASO targets Huntington's disease and SCAs at their genetic source. vicotx.com/our-science/ #ASOs #HuntingtonsDisease
August 12, 2025 at 2:16 PM
What are ASOs? Antisense Oligonucleotides are synthetic molecules that bind to RNA targets, blocking harmful proteins and enabling precise gene modulation. At Vico, our VO659 ASO targets Huntington's disease and SCAs at their genetic source. vicotx.com/our-science/ #ASOs #HuntingtonsDisease
BIO 2026 has been a productive week for Vico. A strong slate of meetings with partners across biotech and pharma, the team has enjoyed sharing updates on progress at Vico and the continued advancement of VO659. Looking forward to the remainder of the conference.
#BIO2026 #BIOInternationalConvention
#BIO2026 #BIOInternationalConvention
June 24, 2026 at 3:15 PM
BIO 2026 has been a productive week for Vico. A strong slate of meetings with partners across biotech and pharma, the team has enjoyed sharing updates on progress at Vico and the continued advancement of VO659. Looking forward to the remainder of the conference.
#BIO2026 #BIOInternationalConvention
#BIO2026 #BIOInternationalConvention
Thank you Labiotech for including VO659, our allele-preferential ASO therapy for severe neurological disorders, such as Huntington's disease, driven by CAG-repeat expansions. Proud to be in this article focused on the companies behind treatments for genetic diseases. www.labiotech.eu/best-biotech...
Which biotech companies are gaining traction in genetic diseases?
Meet 12 biotech companies with promising genetic disease therapies that successfully closed funding rounds recently.
www.labiotech.eu
July 25, 2025 at 6:33 PM
Thank you Labiotech for including VO659, our allele-preferential ASO therapy for severe neurological disorders, such as Huntington's disease, driven by CAG-repeat expansions. Proud to be in this article focused on the companies behind treatments for genetic diseases. www.labiotech.eu/best-biotech...
VO659 is designed to directly target the expanded CAG repeat that drives polyglutamine disease. By targeting the repeat itself rather than a single disease-associated gene, the same investigational ASO can be evaluated across Huntington’s disease, SCA1 and SCA3.
vicotx.com/our-science/...
vicotx.com/our-science/...
September 17, 2026 at 12:42 PM
VO659 is designed to directly target the expanded CAG repeat that drives polyglutamine disease. By targeting the repeat itself rather than a single disease-associated gene, the same investigational ASO can be evaluated across Huntington’s disease, SCA1 and SCA3.
vicotx.com/our-science/...
vicotx.com/our-science/...
"Vico Therapeutics is heading to two healthcare conferences next week:
📍 Wells Fargo Healthcare Conference | Sept. 8-10 | Boston
📍 Cantor Global Healthcare Conference | Sept. 9–11 | NYC
We look forward to connecting with investors and sharing updates on VO659. Reach out to meet with the Vico team.
"
📍 Wells Fargo Healthcare Conference | Sept. 8-10 | Boston
📍 Cantor Global Healthcare Conference | Sept. 9–11 | NYC
We look forward to connecting with investors and sharing updates on VO659. Reach out to meet with the Vico team.
"
September 3, 2026 at 11:13 AM
"Vico Therapeutics is heading to two healthcare conferences next week:
📍 Wells Fargo Healthcare Conference | Sept. 8-10 | Boston
📍 Cantor Global Healthcare Conference | Sept. 9–11 | NYC
We look forward to connecting with investors and sharing updates on VO659. Reach out to meet with the Vico team.
"
📍 Wells Fargo Healthcare Conference | Sept. 8-10 | Boston
📍 Cantor Global Healthcare Conference | Sept. 9–11 | NYC
We look forward to connecting with investors and sharing updates on VO659. Reach out to meet with the Vico team.
"
Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
https://en.hdbuzz.net/398
https://en.hdbuzz.net/398
February 11, 2025 at 11:03 AM
Interim update from Vico Therapeutics on their CAG-targeting drug, VO659
https://en.hdbuzz.net/398
https://en.hdbuzz.net/398
Other trials in HD:
There are several other promising clinical trials at various stages of development, including Vico Therapeutics – VO659, Alnylam Pharmaceuticals – ALN-HTT02, Skyhawk Therapeutics – SKY-0515, and Spark Therapeutics – SPK-10001. For regular updates, visit HDBuzz at en.hdbuzz.net.
There are several other promising clinical trials at various stages of development, including Vico Therapeutics – VO659, Alnylam Pharmaceuticals – ALN-HTT02, Skyhawk Therapeutics – SKY-0515, and Spark Therapeutics – SPK-10001. For regular updates, visit HDBuzz at en.hdbuzz.net.
HDBuzz – Huntington’s disease research news.
en.hdbuzz.net
July 9, 2025 at 12:56 PM
Other trials in HD:
There are several other promising clinical trials at various stages of development, including Vico Therapeutics – VO659, Alnylam Pharmaceuticals – ALN-HTT02, Skyhawk Therapeutics – SKY-0515, and Spark Therapeutics – SPK-10001. For regular updates, visit HDBuzz at en.hdbuzz.net.
There are several other promising clinical trials at various stages of development, including Vico Therapeutics – VO659, Alnylam Pharmaceuticals – ALN-HTT02, Skyhawk Therapeutics – SKY-0515, and Spark Therapeutics – SPK-10001. For regular updates, visit HDBuzz at en.hdbuzz.net.
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Wednesday, February 25, 2026
By: Salong Debbarma on Wednesday, February 25, 2026
Vico Therapeutics initiates patient dosing for VO659 Phase I/IIa trial
Vico Therapeutics has started patient dosing in an expanded cohort for its Phase I/IIa trial of VO659 in Huntington’s disease, SCA3 and SCA1.
www.clinicaltrialsarena.com
February 25, 2026 at 6:52 PM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Wednesday, February 25, 2026
By: Salong Debbarma on Wednesday, February 25, 2026
Director of Analytical Chemistry Paul Koevoets will present at Precision Analytics for Biologics, the upcoming Waters Biopharma Seminar. His talk will highlight impurity profiling of VO659 and analytical approaches supporting next-generation oligonucleotide therapeutics.
May 20, 2026 at 4:37 PM
Director of Analytical Chemistry Paul Koevoets will present at Precision Analytics for Biologics, the upcoming Waters Biopharma Seminar. His talk will highlight impurity profiling of VO659 and analytical approaches supporting next-generation oligonucleotide therapeutics.
Amsterdam recap (#Oligonucleotides for CNS Summit): Thanks to all who joined CSO Nicole Datson’s talk on VO659. She discussed VO659’s unique MoA, IND-enabling work and early clinical studies. Great discussions on challenges and opportunities for oligonucleotide therapeutics in the CNS space.
May 1, 2026 at 11:33 AM
Amsterdam recap (#Oligonucleotides for CNS Summit): Thanks to all who joined CSO Nicole Datson’s talk on VO659. She discussed VO659’s unique MoA, IND-enabling work and early clinical studies. Great discussions on challenges and opportunities for oligonucleotide therapeutics in the CNS space.
Vico CSO Nicole Datson, PhD, will speak at the Oligonucleotides for CNS Summit (Apr 21–23, Amsterdam). She’ll share how VO659 is advancing from preclinical work to Phase 1/2a, and innovations in ASO chemistry for CNS delivery. Connect if you’re attending!
March 24, 2026 at 11:10 AM
Vico CSO Nicole Datson, PhD, will speak at the Oligonucleotides for CNS Summit (Apr 21–23, Amsterdam). She’ll share how VO659 is advancing from preclinical work to Phase 1/2a, and innovations in ASO chemistry for CNS delivery. Connect if you’re attending!
A look back at CHDI’s HD Therapeutics Conference, where our CSO Nicole Datson, PhD, CMO Scott Schobel, MD, and Associate Director Lodewijk Toonen presented data on VO659, our allele-preferential ASO targeting CAG repeat expansion in polyQ diseases.
#HuntingtonsDisease #RNAtherapeutics
#HuntingtonsDisease #RNAtherapeutics
March 23, 2026 at 1:09 PM
A look back at CHDI’s HD Therapeutics Conference, where our CSO Nicole Datson, PhD, CMO Scott Schobel, MD, and Associate Director Lodewijk Toonen presented data on VO659, our allele-preferential ASO targeting CAG repeat expansion in polyQ diseases.
#HuntingtonsDisease #RNAtherapeutics
#HuntingtonsDisease #RNAtherapeutics
Vico Therapeutics has initiated twice-annual dosing of VO659 in our Phase 1/2 trial in HD, SCA3 & SCA1.
U.S. FDA IND cleared; U.S. trial launch planned this year.
New data are being presented this week at the 21st Annual HD Therapeutics Conference.
bit.ly/3ZTw5y2
U.S. FDA IND cleared; U.S. trial launch planned this year.
New data are being presented this week at the 21st Annual HD Therapeutics Conference.
bit.ly/3ZTw5y2
Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1 – Vico Therapeutics
FDA clearance of IND application for VO659 with plans to initiate US-based clinical trial later this year New data highlight distinctive mechanism of action of
bit.ly
February 24, 2026 at 1:13 PM
Vico Therapeutics has initiated twice-annual dosing of VO659 in our Phase 1/2 trial in HD, SCA3 & SCA1.
U.S. FDA IND cleared; U.S. trial launch planned this year.
New data are being presented this week at the 21st Annual HD Therapeutics Conference.
bit.ly/3ZTw5y2
U.S. FDA IND cleared; U.S. trial launch planned this year.
New data are being presented this week at the 21st Annual HD Therapeutics Conference.
bit.ly/3ZTw5y2
Vico Associate Director R&D Lodewijk Toonen will speak at DARS 2025 on “(Pre)clinical Development of an ASO for PolQ Disorders,” highlighting VO659, our ASO designed to reduce toxic CAG repeat transcripts in polyglutamine diseases while preserving normal function.
vicotx.com/pipeline/vo6...
vicotx.com/pipeline/vo6...
December 9, 2025 at 6:32 PM
Vico Associate Director R&D Lodewijk Toonen will speak at DARS 2025 on “(Pre)clinical Development of an ASO for PolQ Disorders,” highlighting VO659, our ASO designed to reduce toxic CAG repeat transcripts in polyglutamine diseases while preserving normal function.
vicotx.com/pipeline/vo6...
vicotx.com/pipeline/vo6...